Subscribe To
ABMD / Abiomed CEO discusses company growth and combining products with supportive technology
ABMD News
By Zacks Investment Research
December 22, 2022
3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line. more_horizontal
By Zacks Investment Research
September 2, 2022
3 Reasons to Hold Abiomed (ABMD) Stock in Your Portfolio
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line. more_horizontal
By Zacks Investment Research
June 17, 2022
Here's Why You Should Hold on to Abiomed (ABMD) Stock For Now
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line. more_horizontal
By Zacks Investment Research
May 16, 2022
Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line. more_horizontal
By CNBC Television
March 28, 2022
Abiomed CEO discusses company growth and combining products with supportive technology
The "Mad Money" host spoke with Abiomed CEO Mike Minogue on Monday's episode of the show. more_horizontal
By Zacks Investment Research
March 15, 2022
Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line. more_horizontal
By Seeking Alpha
February 3, 2022
Abiomed Inc. (ABMD) CEO Mike Minogue on Q3 2022 Results - Earnings Call Transcript
Abiomed Inc. (ABMD) CEO Mike Minogue on Q3 2022 Results - Earnings Call Transcript more_horizontal
By Seeking Alpha
February 3, 2022
Abiomed Inc. (ABMD) CEO Mike Minogue on Q3 2022 Results - Earnings Call Transcript
Abiomed Inc. (ABMD) CEO Mike Minogue on Q3 2022 Results - Earnings Call Transcript more_horizontal